For laboratory research use only. Not for human or veterinary use. This is educational reference information, not medical advice.
Research Database / Peptides / TB-500
TB-500 · Thymosin Beta-4 fragment (actin-binding region)

TB-500

Based on the actin-binding domain of Thymosin Beta-4; investigated in preclinical regeneration research.
Tissue-Derived Peptides
Overview Research Publications Laboratory FAQ References
Overview
Scientific nameThymosin Beta-4 fragment (actin-binding region)
SynonymsTB4 fragment
AbbreviationTB-500
CAS Number77591-33-4
Molecular weight889.02 g/mol (average)
Sequence (one-letter)LKKTETQ
Length7 residues
OriginSynthetic peptide (actin-binding region of Thymosin Beta-4)
PubChem CID62707662
2D / 3D structure
2D chemical structure of TB-500

Interactive sequence

Select a residue to see its amino acid.
Research Summary

Mechanisms under investigation

The following are areas of ongoing preclinical investigation. They describe hypotheses and observations reported in the literature, not established clinical effects.

Actin SequestrationCell Migration
Evidence tiers below reflect how much has been studied in each model type. Counts describe research volume — they do not indicate proven efficacy, safety, or clinical consensus.

Evidence base (transparent counts)

Cellular studies 1 publication
Animal studies 2 publications
Human observational reports 0 publications
Controlled human trials 0 publications
Review articles 1 publication

Research timeline

  • 1965 — Thymosin fraction first isolated from thymus tissue.
  • 1981 — Thymosin Beta-4 characterized as an actin-sequestering peptide.
  • 2000 — Actin-binding fragment (TB-500 region) studied for cell migration and repair.
  • 2015 — Expanded preclinical studies of tissue-repair and angiogenic endpoints.
Publication Library

Selected literature

Filter by study model. Each record is classified for the evidence base above.

2014
Review article surveying the thymosin beta-4 preclinical literature.Review · PubMed (24339784)
2004
In vitro study examining thymosin beta-4, actin regulation, and endothelial cell migration endpoints.Cellular · fibroblast culture · PubMed (15037013)
2003
Preclinical study reporting dermal wound closure endpoints in aged and genetically diabetic mice administered thymosin beta-4.Animal · rat · PubMed (12581423)
1999
Preclinical rat study reporting full-thickness dermal wound closure measurements after thymosin beta-4 administration.Animal · rat · PubMed (10469335)

Each record maps to a structured evidence row with study model, species, and support level.

Laboratory Information

Handling and reference

Storage

Lyophilized: store at -20 C protected from light. Reconstituted: refrigerate and use within the reported stability window.

Stability

Lyophilized powder is comparatively stable; reconstituted solutions are sensitive to temperature and freeze-thaw.

Solubility

Reported soluble in water.

Handling

Use aseptic technique; swirl gently rather than vortexing. For in vitro / research use only.

Molecular weight calculator

Average-mass estimate from a one-letter sequence.

Reconstitution calculator

Laboratory concentration only. Not dosing guidance.

Frequently Asked Questions
What is TB-500?
TB-500 is a synthetic peptide based on the actin-binding region of Thymosin Beta-4, studied in preclinical (cellular and animal) regeneration models. For laboratory research use only.
What research models has it been studied in?
The literature indexed here is predominantly cellular (in vitro) and animal studies. See the evidence base and publication library above for the transparent counts by study model.
Is there controlled human clinical trial evidence?
Controlled human clinical trials are counted separately in the evidence base above. Cellular and animal findings do not establish human clinical effects.
How is it stored and handled in a laboratory?
Lyophilized: store at -20 C protected from light. Reconstituted: refrigerate and use within the reported stability window.
Is this intended for human use?
No. All information and materials are for laboratory research use only — not for human or veterinary use, and not intended to diagnose, treat, cure, or prevent any disease.
Documentation

Research material & documentation

This profile is an educational reference. Lot-level laboratory documentation for materials supplied by Peptide Titans is published openly.

TB-500 research material →  ·  Lot-specific Certificates of Analysis →  ·  How lots are tested →

References and Citation

Evidence records

  1. Review article surveying the thymosin beta-4 preclinical literature. (2014) — review — PubMed.
  2. In vitro study examining thymosin beta-4, actin regulation, and endothelial cell migration endpoints. (2004) — in vitro — PubMed.
  3. Preclinical study reporting dermal wound closure endpoints in aged and genetically diabetic mice administered thymosin beta-4. (2003) — in vivo — PubMed.
  4. Preclinical rat study reporting full-thickness dermal wound closure measurements after thymosin beta-4 administration. (1999) — in vivo — PubMed.

Every record carries a study model, species, support level and review status in the evidence table. Terms used throughout these profiles are defined in the peptide research glossary.

Citation generator

Loading citation...

Explore the full research database

Browse peptide profiles, publications, and laboratory references — all research-only.

For laboratory research use only. Not for human or veterinary use. Educational reference information — not medical advice.